[go: up one dir, main page]

PL3592392T3 - Biomateriały modyfikowane fasl o funkcji immunomodulacyjnej - Google Patents

Biomateriały modyfikowane fasl o funkcji immunomodulacyjnej

Info

Publication number
PL3592392T3
PL3592392T3 PL18764623.7T PL18764623T PL3592392T3 PL 3592392 T3 PL3592392 T3 PL 3592392T3 PL 18764623 T PL18764623 T PL 18764623T PL 3592392 T3 PL3592392 T3 PL 3592392T3
Authority
PL
Poland
Prior art keywords
biomaterials
immunomodulating function
fasl
modified
modified fasl
Prior art date
Application number
PL18764623.7T
Other languages
English (en)
Inventor
Haval Shirwan
Andres J. Garcia
Esma S. Yolcu
Hong Zhao
Devon Headen
Original Assignee
University Of Louisville Research Foundation, Inc.
Georgia Tech Research Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Louisville Research Foundation, Inc., Georgia Tech Research Corporation filed Critical University Of Louisville Research Foundation, Inc.
Publication of PL3592392T3 publication Critical patent/PL3592392T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/178Lectin superfamily, e.g. selectins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/15Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37Digestive system
    • A61K35/39Pancreas; Islets of Langerhans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M3/00Tissue, human, animal or plant cell, or virus culture apparatus
    • C12M3/02Tissue, human, animal or plant cell, or virus culture apparatus with means providing suspensions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Nutrition Science (AREA)
PL18764623.7T 2017-03-10 2018-03-09 Biomateriały modyfikowane fasl o funkcji immunomodulacyjnej PL3592392T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762469802P 2017-03-10 2017-03-10
PCT/US2018/021742 WO2018165547A1 (en) 2017-03-10 2018-03-09 Fasl-engineered biomaterials with immunomodulatory function

Publications (1)

Publication Number Publication Date
PL3592392T3 true PL3592392T3 (pl) 2024-03-18

Family

ID=63448048

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18764623.7T PL3592392T3 (pl) 2017-03-10 2018-03-09 Biomateriały modyfikowane fasl o funkcji immunomodulacyjnej

Country Status (18)

Country Link
US (2) US11602547B2 (pl)
EP (2) EP3592392B1 (pl)
JP (1) JP7335821B2 (pl)
CN (2) CN118697854A (pl)
AU (1) AU2018230474B2 (pl)
CA (1) CA3055908A1 (pl)
DK (1) DK3592392T3 (pl)
ES (1) ES2963331T3 (pl)
FI (1) FI3592392T3 (pl)
HR (1) HRP20231297T1 (pl)
HU (1) HUE064306T2 (pl)
LT (1) LT3592392T (pl)
PL (1) PL3592392T3 (pl)
PT (1) PT3592392T (pl)
RS (1) RS64754B1 (pl)
SI (1) SI3592392T1 (pl)
SM (1) SMT202300437T1 (pl)
WO (1) WO2018165547A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020112904A1 (en) * 2018-11-26 2020-06-04 Massachusetts Institute Of Technology Compositions and methods for immune tolerance
WO2022011125A1 (en) * 2020-07-08 2022-01-13 Georgia Tech Research Corporation Crosslinked hydrogel for immune checkpoint blockade delivery
EP4522236A1 (en) * 2022-05-12 2025-03-19 Itolerance, Inc. Transient sirolimus with fasl microgels
WO2024182722A1 (en) * 2023-03-01 2024-09-06 Georgia Tech Research Corporation Therapeutic nanoparticles for solid organ immune acceptance
WO2024249293A1 (en) * 2023-05-26 2024-12-05 The Curators Of The University Of Missouri Controlled release of therapeutic proteins for immunomodulation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022951A (en) 1995-04-11 2000-02-08 Univ Boston Streptavidin mutants
EP0842948B1 (en) * 1995-06-30 2009-04-22 Mochida Pharmaceutical Co., Ltd. ANTIFas LIGAND ANTIBODIES AND ASSAY METHOD BY USING THE SAME
GB9523469D0 (en) * 1995-11-16 1996-01-17 Sandoz Ltd Organic compounds
US7927602B2 (en) * 2002-07-23 2011-04-19 University Of Louisville Research Foundation, Inc. Fas ligand-avidin/streptavidin fusion proteins
US7238360B2 (en) 2000-06-30 2007-07-03 Unversity Of Louisville Research Foundation, Inc. Alteration of cell membrane with B7
WO2004049907A2 (en) * 2002-11-27 2004-06-17 University Of Louisville Research Foundation Compositions and methods for treating transplants
CA2619048A1 (en) * 2005-08-15 2007-02-22 The Regents Of The University Of California Vegf-activated fas ligands
WO2011041240A1 (en) * 2009-09-30 2011-04-07 The Brigham And Women's Hospital, Inc. Tissue transplant compositions and methods for use
SG177761A1 (en) 2009-07-31 2012-03-29 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels
RU2557533C2 (ru) * 2009-11-06 2015-07-20 Ск Биофармасъютиклс Ко., Лтд. Способы лечения синдрома фибромиалгии
WO2014056926A1 (en) 2012-10-11 2014-04-17 Ascendis Pharma A/S Hydrogel prodrugs
EP3041934A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Chimeric polynucleotides
US9381217B2 (en) 2013-09-09 2016-07-05 Georgia Tech Research Corporation Microgels for encapsulation of cells and other biologic agents
WO2016205714A1 (en) * 2015-06-19 2016-12-22 University Of Louisville Research Foundation, Inc. Immunomodulation for the long term prevention and treatment of autoimmune diseases and foreign tissue rejection

Also Published As

Publication number Publication date
EP4299749A2 (en) 2024-01-03
EP4299749A3 (en) 2024-03-27
JP2020511531A (ja) 2020-04-16
SMT202300437T1 (it) 2024-01-10
PT3592392T (pt) 2023-11-23
JP7335821B2 (ja) 2023-08-30
EP3592392A4 (en) 2020-12-16
EP3592392B1 (en) 2023-09-13
US20230310510A1 (en) 2023-10-05
HUE064306T2 (hu) 2024-02-28
ES2963331T3 (es) 2024-03-26
LT3592392T (lt) 2024-01-25
WO2018165547A1 (en) 2018-09-13
CN110582560A (zh) 2019-12-17
AU2018230474B2 (en) 2023-08-03
FI3592392T3 (fi) 2023-11-09
CA3055908A1 (en) 2018-09-13
DK3592392T3 (da) 2023-10-23
SI3592392T1 (sl) 2024-02-29
US20200046780A1 (en) 2020-02-13
CN118697854A (zh) 2024-09-27
HRP20231297T1 (hr) 2024-02-02
US11602547B2 (en) 2023-03-14
RS64754B1 (sr) 2023-11-30
CN110582560B (zh) 2024-06-14
EP3592392A1 (en) 2020-01-15
AU2018230474A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
EP3684438A4 (en) DIRECTED FLUIDS
IL293377A (en) Hsd17b13 variants and uses thereof
LT3368534T (lt) Valbenazino ditozilatas ir jo polimorfai
LT3394065T (lt) Tetrahidropiranilamino-pirolopirimidinonas ir jo panaudojimo būdai
PL3592392T3 (pl) Biomateriały modyfikowane fasl o funkcji immunomodulacyjnej
EP3687961A4 (en) HIGH SOLID SUSPENSION FERTILIZER
DK3393537T3 (da) Biomedicinske materialer med høj styrke
EP3727258C0 (en) Absorbent article with reduced sagging
MA49905A (fr) Polyesteramines et polyesterquats
HUP1700509A2 (en) Hinge with stop positions
DK3709940T3 (da) Beholdere med rivningstyrende egenskaber
EP3546581A4 (en) MICRO-ORGANISMECORYNEBACTERIUM
EP3729254A4 (en) PROGRAMMABLE MULTIPLICATION-ADDITION NETWORK EQUIPMENT
EP3694515A4 (en) ZINC IONOPHORES AND ASSOCIATED USES
EP3369371C0 (de) Multisensordress und deren verwendung
HUE042677T2 (hu) Sínelrendezés kerek testekkel
DE112017003254A5 (de) Biomaterial
ITUB20153578A1 (it) Dispositivo di illuminazione e corrispondente procedimento
DE112018001077A5 (de) Biopsienadelführung mit zweistufiger fixierung
PL3250234T3 (pl) Rekombinowany mdv1 i jego zastosowania
EP3712225A4 (en) INFRARED ABSORBING OBJECT
DK3364119T3 (da) Omdirigeringsstykke
GB2570027B (en) Relaxer with methionine
ES1189209Y (es) Mueble de discoteca con guardarropia
GB201708860D0 (en) ZoneFeeder with zoneLock